Echinaforce Study to Investigate Explorative Pharmacology and Effectiveness to Prevent From Enveloped Virus Infections

PHASE4CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

November 20, 2020

Primary Completion Date

May 29, 2021

Study Completion Date

May 29, 2021

Conditions
Respiratory Tract InfectionsCommon Cold
Interventions
DRUG

Echinaforce Chewable tablets

"Preventive treatment: 3X2 EC tablets daily during 2 + 2 months of prevention after run-in of 1 week and intermittent treatment break of 1 week without treatment + 1 month of voluntary follow-up prevention.~Acute treatment: 5 X 2 EC tablets daily for max. 10 days per individual vRTI or until symptom resolution."

Trial Locations (1)

1680

Diagnostics and Consultation Center Convex EOOD, Sofia

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

CONVEX CRO

UNKNOWN

collaborator

d.s.h. statistical services GmbH

UNKNOWN

collaborator

MediStat Ltd.

UNKNOWN

collaborator

Biodome Clinical

UNKNOWN

collaborator

Bodimed

UNKNOWN

collaborator

PPES lab epigenetic signaling

UNKNOWN

lead

A. Vogel AG

INDUSTRY

NCT05002179 - Echinaforce Study to Investigate Explorative Pharmacology and Effectiveness to Prevent From Enveloped Virus Infections | Biotech Hunter | Biotech Hunter